Previous close | 52.50 |
Open | 52.50 |
Bid | 52.10 |
Ask | 53.10 |
Strike | 175.00 |
Expiry date | 2024-12-20 |
Day's range | 52.50 - 52.50 |
Contract range | N/A |
Volume | |
Open interest | 32 |
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott Marquis San Diego Marina | 333 West Harbor Dr. San Diego, CA 92101 Research: 26 ResMed-supported abstracts will be presented at ATS. Full list below. Highlights: Treatment of Sleep-Disordered Breathing with Adaptive Servo-Ventilation (READ-ASV) in Opioid Users – a European Registry Sunday May 19, 2024, 9:15 a.m. - 11:15 a.m., SDCC 32A-BPresented
ResMed (RMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.